Cancertain Limited Secures £2.2m to Advance Personalised Cancer Treatment

Cancertain Limited, a UK-based innovator in personalised cancer diagnostics, has successfully raised £2.2m in a recent funding round. The Cheadle-incorporated company, with its headquarters in Manchester, specialises in providing a unique clinical test designed to guide optimal cancer treatment decisions for patients and clinicians.

Founded on 25 January 2017, Cancertain Limited addresses a critical challenge in oncology: the often-sequential and time-consuming process of identifying effective cancer treatments. Many patients currently receive a 'one-size-fits-all' treatment plan, leading to significant anxiety and potential exposure to ineffective or toxic therapies. Cancertain's core offering, the Cancertain™ Assay, leverages advanced 3D cell culture techniques to test standard chemotherapies, targeted therapies, and immunotherapies against a patient's own tumour cells. This approach aims to identify the most effective treatment quickly, reducing unwanted side effects, improving quality of life, and increasing the chances of early recovery. The company prides itself on a rapid turnaround time of just eight working days for its personalised treatment recommendations.

The company operates with a lean team of five employees, according to its LinkedIn profile, and is dedicated to improving patient outcomes through its innovative diagnostic service. While specific revenue or profit/loss figures for Cancertain Limited are not publicly available, its consistent engagement in funding activities underscores its developmental trajectory.

The latest funding round, with an estimated size of £2.2m, saw its allotment date on 20 April 2026, with filings completed on 21 April 2026. The valuation for this specific round has not been disclosed. This substantial capital injection represents a significant step for Cancertain Limited, particularly when viewed against its previous funding history. The company has demonstrated a consistent ability to attract investment since its inception. Prior rounds include: £74.7k on 7 November 2025 (at a valuation of £557.7k), £234k on 16 December 2022, £550.6k on 14 May 2021, and £400.8k on 23 September 2020. Earlier rounds in 2019 saw £63.2k on 22 July, £65k on 16 May, £40k on 2 April, and £85.2k on 5 March, all at a consistent valuation of £2.7m. The company's initial funding in 2017 and 2018 included £73.6k on 5 June 2017 and £20k on 27 March 2018, both at a £1.4m valuation. This latest £2.2m round marks the largest single capital raise for Cancertain Limited to date, indicating growing investor confidence in its technology and market potential.

While previous seed funding rounds for the company (formerly CLYZ Labs) have seen participation from investors such as Catapult Ventures through the GM&C Life Sciences Fund, and individual clinicians under SEIS and EIS Schemes, the specific investors for this £2.2m round have not been announced.

This funding round for Cancertain Limited occurs within a dynamic and evolving UK funding landscape for both biotechnology and health technology sectors. In 2025, the UK biotech sector faced a challenging financing environment, securing £1.9 billion in equity financing, with venture capital representing £1.8 billion, a 13.2% decrease year-on-year. This decline was largely driven by a drop in deal activity, as investors became more selective, focusing capital on a limited number of companies. Despite this, the UK maintained its position as Europe's leading national biotech market, attracting 30% of all European venture financing in 2025.

In contrast, the HealthTech sector in the UK experienced a significant rebound in 2025, with companies raising $1.61 billion in equity funding across 127 rounds, marking a 59.71% rise compared to 2024. This growth indicates a strategic acceleration and structural evolution in the market, driven by regulatory changes, technological maturity in areas like AI, and the deployment of private capital. Both sectors, however, saw a trend towards the concentration of capital in fewer but larger transactions, reflecting a shift towards "high-conviction investment" rather than a "spray and pray" approach.

The UK government's commitment to digital transformation and the NHS's long-term strategic plans are creating a stable and predictable environment for scaling HealthTech solutions, reducing regulatory uncertainty and making the region an attractive destination for capital. Furthermore, regions beyond the traditional "Golden Triangle" of London, Oxford, and Cambridge are seeing the maturation of "Northern Powerhouse" clusters, supported by government initiatives. Cancertain Limited's base in Manchester positions it well within this emerging regional strength, particularly given Manchester's growing reputation as a hub for life sciences and health innovation.

The investment in Cancertain Limited underscores the continued appetite for innovative deep tech and novel science at early stages, even in a selective investment climate. As precision medicine gains traction, moving oncology away from trial-and-error towards evidence-based treatment selection, companies like Cancertain are poised to play a crucial role in improving patient outcomes. This funding will enable Cancertain Limited to further develop and scale its Cancertain™ Assay, contributing to the advancement of personalised cancer care both within the UK and potentially on a global scale.